Metagenomi Therapeutics, Inc. - 8-K Filing

Metagenomi Therapeutics receives FDA IND clearance for MGX-001 hemophilia A program and reports Q3 2026 results. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 10, 2026, 21:07 UTC

Tickers: $MGX

Read the full article at SEC EDGAR

More Regulatory news

AUDIOEYE INC - 10-Q Filing SEC EDGAR · October 26, 2026, 21:11 UTC
ROCKWELL AUTOMATION, INC - 10-K Filing SEC EDGAR · November 12, 2026, 16:35 UTC
United KSK Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 16:29 UTC
AMERICAN SHARED HOSPITAL SERVICES - 8-K Filing SEC EDGAR · November 12, 2026, 16:27 UTC
VIVIC CORP. - 10-K Filing SEC EDGAR · November 12, 2026, 16:26 UTC
WOLVERINE WORLD WIDE INC /DE/ - 10-Q Filing SEC EDGAR · November 12, 2026, 16:24 UTC
BlueOne Technologies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:20 UTC
Newton Golf Company, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:14 UTC
XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC